Therefore, in this work, we focused on SET and sought to determine the role of the SET/PP2A axis in T-ALL by using a SET antagonist, OP449, which has been previously shown to be effective against CLL, non-Hodgkin's lymphoma, CML, and AML cells ex vivo [32, 34]. This evidence concerns the gene PTPA and chronic myelogenous leukemia, BCR-ABL1 positive.